Collaborative Arrangements - Significant collaborative arrangements (Details)
|
1 Months Ended |
12 Months Ended |
|
Dec. 31, 2019
USD ($)
|
Nov. 30, 2019
USD ($)
|
Oct. 31, 2019 |
Jun. 30, 2018
USD ($)
|
Nov. 30, 2017
USD ($)
|
Dec. 31, 2019
USD ($)
Agreement
|
Dec. 31, 2018
USD ($)
|
Dec. 31, 2017
USD ($)
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Cash payments received |
|
|
|
|
|
$ 1,170,947,000
|
$ 1,094,274,000
|
$ 903,374,000
|
| VUMERITY |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Percentage of net sales in royalty payment |
|
|
|
|
|
15.00%
|
|
|
| Maximum percentage of product supplies on net sales |
|
|
100.00%
|
|
|
|
|
|
| Biogen |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Payment received upon the initiation of phase 3 clinical trial |
|
|
|
|
$ 50,000,000.0
|
|
|
|
| Biogen | License |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Cash payments received |
$ 5,000,000.0
|
$ 150,000,000.0
|
|
$ 50,000,000.0
|
$ 28,000,000.0
|
|
|
|
| Percentage of net sales in royalty payment |
|
|
|
|
|
15.00%
|
|
|
| License agreement | Janssen | INVEGA SUSTENNA/XEPLION |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Patent royalty rate (as a percent) |
|
|
|
|
|
1.50%
|
|
|
| Know-how royalty rate resets (as a percent) |
|
|
|
|
|
3.50%
|
|
|
| Period after the date of the first commercial sale of the product for license expiration |
|
|
|
|
|
15 years
|
|
|
| License agreement | Janssen | INVEGA SUSTENNA/XEPLION | Net sales of below $250.0 million |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Know-how royalty rate (as a percent) |
|
|
|
|
|
3.50%
|
|
|
| License agreement | Janssen | INVEGA SUSTENNA/XEPLION | Net sales between $250.0 million and 500.0 million |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Know-how royalty rate (as a percent) |
|
|
|
|
|
5.50%
|
|
|
| License agreement | Janssen | INVEGA SUSTENNA/XEPLION | Net sales greater than $500.0 million |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Know-how royalty rate (as a percent) |
|
|
|
|
|
7.50%
|
|
|
| License agreement | Janssen | INVEGA SUSTENNA/XEPLION | Minimum |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Royalty rate (as a percent) |
|
|
|
|
|
5.00%
|
|
|
| License agreement | Janssen | INVEGA SUSTENNA/XEPLION | Minimum | Net sales between $250.0 million and 500.0 million |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Aggregate worldwide net sales |
|
|
|
|
|
$ 250,000,000
|
|
|
| License agreement | Janssen | INVEGA SUSTENNA/XEPLION | Minimum | Net sales greater than $500.0 million |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Aggregate worldwide net sales |
|
|
|
|
|
$ 500,000,000
|
|
|
| License agreement | Janssen | INVEGA SUSTENNA/XEPLION | Maximum |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Royalty rate (as a percent) |
|
|
|
|
|
9.00%
|
|
|
| License agreement | Janssen | INVEGA SUSTENNA/XEPLION | Maximum | Net sales of below $250.0 million |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Aggregate worldwide net sales |
|
|
|
|
|
$ 250,000,000
|
|
|
| License agreement | Janssen | INVEGA SUSTENNA/XEPLION | Maximum | Net sales between $250.0 million and 500.0 million |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Aggregate worldwide net sales |
|
|
|
|
|
$ 500,000,000
|
|
|
| License agreement | Janssen | RISPERDAL CONSTA |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Royalty rate (as a percent) |
|
|
|
|
|
2.50%
|
|
|
| Period after the date of the first commercial sale of the product for license expiration |
|
|
|
|
|
15 years
|
|
|
| Number of license agreements | Agreement |
|
|
|
|
|
2
|
|
|
| Notice period required to be given before termination of agreement |
|
|
|
|
|
30 days
|
|
|
| Period for resolving default or breach after the receipt of notice for termination of agreement |
|
|
|
|
|
90 days
|
|
|
| License agreement | Acorda |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Milestone payment entitled to be received upon the initiation of phase 3 clinical trial |
1,000,000.0
|
|
|
|
|
$ 1,000,000.0
|
|
|
| Milestone payment entitled to be received upon the acceptance of NDA by the FDA |
1,000,000.0
|
|
|
|
|
1,000,000.0
|
|
|
| Milestone payment entitled to be received upon the approval of NDA by the FDA |
1,500,000
|
|
|
|
|
1,500,000
|
|
|
| Milestone payment entitled to be received upon the first commercial sale |
$ 1,500,000
|
|
|
|
|
$ 1,500,000
|
|
|
| License agreement | Acorda | AMPYRA/ FAMPYRA |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Royalty rate (as a percent) |
|
|
|
|
|
10.00%
|
|
|
| Notice period required to be given before termination of agreement |
|
|
|
|
|
90 days
|
|
|
| Manufacturing and supply agreement | Janssen | RISPERDAL CONSTA |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Period after the date of the first commercial sale of the product for license expiration |
|
|
|
|
|
60 days
|
|
|
| Notice period required to be given before termination of agreement |
|
|
|
|
|
6 months
|
|
|
| Manufacturing and supply agreement | Janssen | RISPERDAL CONSTA | Minimum |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Royalty rate (as a percent) |
|
|
|
|
|
7.50%
|
|
|
| Royalty rate upon termination of manufacturing and supply agreement (as a percent) |
|
|
|
|
|
2.50%
|
|
|
| Manufacturing and supply agreement | Janssen | RISPERDAL CONSTA | Maximum |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Royalty rate upon termination of manufacturing and supply agreement (as a percent) |
|
|
|
|
|
5.00%
|
|
|
| Manufacturing and supply agreement | Acorda | AMPYRA/ FAMPYRA |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Royalty rate (as a percent) |
|
|
|
|
|
8.00%
|
|
|
| Notice period required to be given before termination of agreement |
|
|
|
|
|
12 months
|
|
|
| Manufacturing and supply agreement | Acorda | AMPYRA/ FAMPYRA | Maximum |
|
|
|
|
|
|
|
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
| Percentage of total annual requirement of product that can be obtained from second source manufacturer |
|
|
|
|
|
25.00%
|
|
|